Suppliers and packagers for FML FORTE

FML FORTE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	FML FORTE	fluorometholone	SUSPENSION/DROPS;OPHTHALMIC	019216	NDA	Allergan, Inc.	11980-228-05	1 BOTTLE, DROPPER in 1 CARTON (11980-228-05) / 5 mL in 1 BOTTLE, DROPPER	1986-05-01
Abbvie	FML FORTE	fluorometholone	SUSPENSION/DROPS;OPHTHALMIC	019216	NDA	Allergan, Inc.	11980-228-10	1 BOTTLE, DROPPER in 1 CARTON (11980-228-10) / 10 mL in 1 BOTTLE, DROPPER	1986-05-01

Suppliers and packagers for FML FORTE

Last updated: July 6, 2026

FML FORTE Suppliers: Who Manufactures and Supplies This Prescription Eye Drug?

FML FORTE is an ophthalmic corticosteroid product (fluorometholone) marketed in the US as an eye drop. It is typically supplied through a mix of the brand’s primary manufacturer/labeler and regional distributors, with additional third-party manufacturers supplying finished dosage forms or components depending on contract manufacturing and label ownership.

What companies supply FML FORTE eye drops in the US market?

Answer: The market supply chain for FML FORTE consists of (1) the FDA labeler (the firm responsible for the product listing), (2) the finished-dose manufacturer(s) used for commercial production, and (3) wholesale distributors that source from the labeler/manufacturer and distribute to pharmacies and clinics.

How to identify the “supplier” in regulatory terms

For pharma supply diligence, “supplier” is usually one of these:

• FDA labeler: shown on the product’s FDA listing for NDC distribution.
• Manufacturer: can be the labeler itself or a contract manufacturing organization (CMO) listed in FDA product records.
• Distributor/wholesaler: not always listed in FDA records; identified via commercial channel mappings and NDC distribution data.

FML FORTE key supply roles

• Labeler/holder of marketed supply responsibility (FDA-registered listing)
• Finished-dose manufacturer (plants that produce the ophthalmic solution)
• Packaging site (bottling, dropper/closure assembly, secondary packaging)

Who is the FDA labeler for FML FORTE, and what does that imply for sourcing?

Answer: The FDA labeler is the best proxy for the primary “supplier” you will see in US procurement, because most channel inventory originates from the labeler’s distribution network.

Why labeler identity matters for contracting and licensing

• Contracting for supply, OTC substitution, or sourcing assurance typically starts with the labeler.
• Patent and exclusivity linkage is usually anchored to the same company that holds marketing rights and controls supply continuity.
• Recalls and supply disruptions propagate through the labeler’s distribution footprint.

Which manufacturing sites produce FML FORTE (finished dosage and packaging)?

Answer: FML FORTE production is handled by either a vertically integrated labeler or a CMO that supplies the finished ophthalmic dosage form. Packaging is often performed at one or more secondary sites, depending on packaging line capacity and regulatory controls.

What to expect in manufacturing records

• Primary bulk manufacturing site for the ophthalmic solution
• Compounding/filling line site for the sterile or conditioned liquid formulation
• Packaging and labeling site for cartons, closures, and patient labeling

Are there multiple sources of FML FORTE, or is it single-sourced?

Answer: Many ophthalmic products have single primary manufacturing lines early in lifecycle, then add additional CMOs or line partners as distribution scales. Whether FML FORTE is single-sourced or multi-sourced depends on whether the labeler uses multiple manufacturers across NDCs.

What determines multi-sourcing

• NDC-level manufacturer listings
• Seasonal demand and channel fill rates
• Contract manufacturing rotation and redundant filling capacity
• Regulatory changes requiring comparability batches at alternate sites

What generic or alternative suppliers compete with FML FORTE?

Answer: Competition in this therapeutic space comes from other fluorometholone ophthalmic suspensions/solutions and alternative corticosteroid eye drops. “Supplier” in competitive terms means the labelers of equivalent NDCs and their underlying manufacturing partners.

Competitive supply dynamics

• Generic ophthalmic corticosteroids can be supplied by multiple companies across NDCs.
• Private label sourcing can exist for distributors depending on wholesaler contracts.
• Substitution risk depends on equivalence (active, concentration, dosage form) and pharmacy formulary placement.

How do distributor channels affect who can supply FML FORTE for contracts?

Answer: Even when the labeler is clear, procurement often depends on:

• Contract terms with authorized wholesalers
• Allocation policies during supply strain
• Availability of specific NDCs (different strengths or container sizes)

Channel mapping for procurement

• Authorized wholesalers: primary route for stable supply.
• Specialty distributors: sometimes involved for ophthalmology-heavy channels.
• Group purchasing organizations: can shift purchasing toward specific distributors, not necessarily different manufacturers.

Key takeaways

• “Supplier” for FML FORTE in practical procurement terms is anchored to the FDA labeler and the FDA-identified manufacturer(s) behind each NDC.
• Real-world sourcing depends on NDC-level listing, whether manufacturing is single-site or multi-site, and which authorized wholesalers hold allocation and fill rate responsibility.
• Competitive supply in ophthalmic corticosteroids is driven by labeler NDC listings and the set of CMOs producing equivalent dosage forms.

FAQs

1. How can a buyer verify the manufacturer behind an FML FORTE NDC?
2. Do ophthalmic fluorometholone products use contract manufacturing, and how does that show up in FDA records?
3. What determines whether FML FORTE is eligible for substitution at the pharmacy level?
4. How do FDA labeling/packaging differences create multiple “suppliers” for the same brand?
5. What supply-chain signals indicate impending shortages of FML FORTE (allocation, backorders, NDC-level changes)?

References

1. FDA. “Drug Listings: FDA-Approved Drug Products.” US Food and Drug Administration.
2. FDA. “NDC Directory (National Drug Code) and Drug Registration and Listing.” US Food and Drug Administration.